Literature DB >> 17696574

Diagnosis and treatment of agoraphobia with panic disorder.

Giulio Perugi1, Franco Frare, Cristina Toni.   

Abstract

Agoraphobia with panic disorder is a phobic-anxious syndrome where patients avoid situations or places in which they fear being embarrassed, or being unable to escape or get help if a panic attack occurs. During the last half-century, agoraphobia has been thought of as being closely linked to the recurring panic attack syndrome, so much so that in most cases it appears to be the typical development or complication of panic disorder. Despite the high prevalence of agoraphobia with panic disorder in patients in primary-care settings, the condition is frequently under-recognised and under-treated by medical providers. Antidepressants have been demonstrated to be effective in preventing panic attacks, and in improving anticipatory anxiety and avoidance behaviour. These drugs are also effective in the treatment of the frequently coexisting depressive symptomatology. Among antidepressant agents, SSRIs are generally well tolerated and effective for both anxious and depressive symptomatology, and these compounds should be considered the first choice for short-, medium- and long-term pharmacological treatment of agoraphobia with panic disorder. The few comparative studies conducted to date with various SSRIs reported no significant differences in terms of efficacy; however, the SSRIs that are less liable to produce withdrawal symptoms after abrupt discontinuation should be considered the treatments of first choice for long-term prophylaxis. Venlafaxine is not sufficiently studied in the long-term treatment of panic disorder, while TCAs may be considered as a second choice of treatment when patients do not seem to respond to or tolerate SSRIs. High-potency benzodiazepines have been shown to display a rapid onset of anti-anxiety effect, having beneficial effects during the first few days of treatment, and are therefore useful options for short-term treatment; however, these drugs are not first-choice medications in the medium and long term because of the frequent development of tolerance and dependence phenomena. Cognitive-behavioural therapy is the best studied non-pharmacological approach and can be applied to many patients, depending on its availability.

Entities:  

Mesh:

Year:  2007        PMID: 17696574     DOI: 10.2165/00023210-200721090-00004

Source DB:  PubMed          Journal:  CNS Drugs        ISSN: 1172-7047            Impact factor:   5.749


  190 in total

Review 1.  Flawed meta-analyses comparing psychotherapy with pharmacotherapy.

Authors:  D F Klein
Journal:  Am J Psychiatry       Date:  2000-08       Impact factor: 18.112

Review 2.  Cognitive-behavioral therapy and the treatment of panic disorder: efficacy and strategies.

Authors:  Michael W Otto; Christen Deveney
Journal:  J Clin Psychiatry       Date:  2005       Impact factor: 4.384

3.  Long-term outcome in cognitive-behavioral treatment of panic disorder: clinical predictors and alternative strategies for assessment.

Authors:  T A Brown; D H Barlow
Journal:  J Consult Clin Psychol       Date:  1995-10

4.  One-year follow-up of panic disorder. Outcome and prognostic factors.

Authors:  W Maier; R Buller
Journal:  Eur Arch Psychiatry Neurol Sci       Date:  1988

5.  Panic disorder: residual symptoms after the acute attacks abate.

Authors:  W Katon; P P Vitaliano; K Anderson; M Jones; J Russo
Journal:  Compr Psychiatry       Date:  1987 Mar-Apr       Impact factor: 3.735

6.  Frustrating patients: physician and patient perspectives among distressed high users of medical services.

Authors:  E H Lin; W Katon; M Von Korff; T Bush; P Lipscomb; J Russo; E Wagner
Journal:  J Gen Intern Med       Date:  1991 May-Jun       Impact factor: 5.128

7.  Agoraphobia: a follow-up study four years after treatment.

Authors:  P M Emmelkamp; A C Kuipers
Journal:  Br J Psychiatry       Date:  1979-04       Impact factor: 9.319

Review 8.  Clonazepam: new uses and potential problems.

Authors:  L S Cohen; J F Rosenbaum
Journal:  J Clin Psychiatry       Date:  1987-10       Impact factor: 4.384

9.  Treatment of agoraphobia with group exposure in vivo and imipramine.

Authors:  C M Zitrin; D F Klein; M G Woerner
Journal:  Arch Gen Psychiatry       Date:  1980-01

10.  Psychiatric disorder and functional somatic symptoms as predictors of health care use.

Authors:  G E Simon
Journal:  Psychiatr Med       Date:  1992
View more
  5 in total

1.  Self-guided digital treatment with virtual reality for panic disorder and agoraphobia: a study protocol for a randomized controlled trial.

Authors:  Jari Planert; Alla Machulska; Anne-Sophie Hildebrand; Kati Roesmann; Esra Otto; Tim Klucken
Journal:  Trials       Date:  2022-05-21       Impact factor: 2.728

2.  Antianxiety medications for the treatment of complex agoraphobia: pharmacological interventions for a behavioral condition.

Authors:  Giampaolo Perna; Silvia Daccò; Roberta Menotti; Daniela Caldirola
Journal:  Neuropsychiatr Dis Treat       Date:  2011-10-19       Impact factor: 2.570

3.  Cross-sectional study of propofol dose during intravenous sedation for dental surgery in patients with long-term oral benzodiazepine therapy: A secondary publication.

Authors:  Toshiaki Fujisawa; Kazuki Miyata; Yukie Nitta; Akifumi Terui; Emi Ishikawa; Eri Hamaya; Keiichiro Wakana; Shigeru Takuma; Makiko Shibuya
Journal:  Clin Exp Dent Res       Date:  2022-06-19

4.  Prevalence and Clinical Correlates of Comorbid Anxiety and Panic Disorders in Patients with Parkinson's Disease.

Authors:  Camilla Elefante; Giulio Emilio Brancati; Silvia Bacciardi; Sonia Mazzucchi; Eleonora Del Prete; Giovanni Palermo; Daniela Frosini; Ubaldo Bonuccelli; Roberto Ceravolo; Lorenzo Lattanzi; Icro Maremmani; Giulio Perugi
Journal:  J Clin Med       Date:  2021-05-25       Impact factor: 4.241

5.  Evaluation of a practice team-supported exposure training for patients with panic disorder with or without agoraphobia in primary care - study protocol of a cluster randomised controlled superiority trial.

Authors:  Jochen Gensichen; Thomas S Hiller; Jörg Breitbart; Tobias Teismann; Christian Brettschneider; Ulrike Schumacher; Alexander Piwtorak; Hans-Helmut König; Heike Hoyer; Nico Schneider; Mercedes Schelle; Wolfgang Blank; Paul Thiel; Michel Wensing; Jürgen Margraf
Journal:  Trials       Date:  2014-04-06       Impact factor: 2.279

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.